Biotech Values

[Whalatane]

CFRX. Dew, my mother developed a community acquired infection while in a nursing home and had to be hospitalized . My uncle died from an infection related to his hip transplant ( both of these 10 yrs ago )

CFRX's Results seem better when Exabacase is added to SOC than with SOC alone .

Exebacase is being evaluated in patients with relapsing prosthetic joint Staph infections.
• Four patients were treated with exebacase administered intra-articularly. All had several previous prosthetic knee revisions, without prosthesis loosening. Two had clinical signs of septic arthritis (panel A); the two others had fistula. No adverse events occurred during arthroscopy.
• After 1 year follow up, the outcome was favorable in the two septic arthritis patients, with disappearance of clinical signs of septic arthritis (panel B).
Persistent MRSA Bacteremia in COVID-19 Infected Patients
AB
• Exebacase is being offered under an expended access program to Phase 3 clinical sites for the treatment of persistent MRSA infections in COVID-19 infected patients
• COVID-19 infected patients are at risk for developing MRSA superinfections, leading to septic shock and death. Staph aureus has been one of the most common pathogenic causes of bacterial infections in patients suffering from severe influenza infections(2).
In China, over the course of the COVID-19 pandemic, up to 50% of patients who died experienced a secondary infection(3,4).

We need better antibiotics to add to SOC
JMO

Kiwi